Exhibit 99.1
August 18, 2008 — Frequently Asked Questions and Answers – (FAQs)
From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.
| | | |
Q | | What are the IMS prescription volumes for VYTORIN and ZETIA? |
| | | |
A | | U.S. Total Prescription Volume (000’s) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | January | | February | | March | | April | | May | | June | | July |
| | | 2008 | | 2008 | | 2008 | | 2008 | | 2008 | | 2008 | | 2008 |
| |
| Cholesterol Management Market | | | 20,402 | | | | 18,941 | | | | 19,687 | | | | 19,543 | | | | 19,804 | | | | 19,398 | | | | 20,294 | |
| Total Merck/Schering-Plough Franchise | | | 3,205 | | | | 2,773 | | | | 2,803 | | | | 2,492 | | | | 2,463 | | | | 2,352 | | | | 2,378 | |
| VYTORIN | | | 1,839 | | | | 1,597 | | | | 1,610 | | | | 1,420 | | | | 1,404 | | | | 1,330 | | | | 1,339 | |
| ZETIA | | | 1,366 | | | | 1,176 | | | | 1,193 | | | | 1,072 | | | | 1,060 | | | | 1,022 | | | | 1,039 | |
Source: IMS’National Prescription Audit Plus (NPA+)as of August 13, 2008, which includes routine refinements by IMS to previously published data.
DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.
Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in Schering-Plough’s 10-Q for the quarterly period ended June 30, 2008, filed August 1, 2008.
Page 6
